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The article by Pawlik and colleagues in this issue of
Annals of Surgical Oncology provides objective data
in support of a multimodality approach to the care of
the pancreatic cancer patient. The current manuscript
builds on the long-standing tradition of excellence in
the care of this disease established by John Cameron
and takes advantage of their unique institutional
talents in diagnostic imaging (Elliot Fishman) and
pathology (Ralph Hruban). Indeed, an obvious po-
tential criticism of this manuscript is that they can do
things at Johns Hopkins which simply can not be
done elsewhere and therefore, this work is not
translatable to other centers with less experience.
However, we would argue that the speciﬁc results
presented by Pawlik and colleagues are translatable
to other less experienced centers if deﬁnitions and
templates were to be developed and uniformly ap-
plied to the care of patients with pancreatic cancer
throughout this country. For example:
1. The clinical/radiographic stage of disease was
changed in 19% of patients after review of pre-
referral imaging and when necessary, repeat
imaging interpreted by an experienced radiologist.
To assign a clinical/radiographic stage to a patient
(and their CT images) assumes that the multidis-
ciplinary group has agreed on the deﬁnitions of
resectable, locally advanced (to include borderline
resectable) and metastatic disease. As the manu-
script infers, this is rarely the case. In fact, there
was recently a consensus conference coordinated
by Dr. Jean-Nicolas Vauthey and supported by
the SSO and the AHPBA to generate working
deﬁnitions of these stages of disease; this impor-
tant manuscript is forthcoming. If physicians of
different specialties can agree on the radiographic
stages of disease, then stage speciﬁc treatment is
possible, and over time, more uniform. The
clinical/radiographic staging system in use at our
institution is presented in Table 1. However,
accurate staging is possible only if the cross-
sectional imaging studies are done well and
interpreted accurately. Accurate interpretation of
CT or MRI images by radiologists of signiﬁcantly
less experience than Dr. Fishman requires a report
template to insure that all necessary information is
contained in the report – information needed to
accurately apply the proper stage of disease. The
template in use at our institution appears in Table
2. Such working deﬁnitions allow for patients to
be initially evaluated by physicians of any spe-
cialty and their disease extent accurately deter-
mined.
2. The treatment recommendation was altered in
24% of patients based on repeat imaging and
multidisciplinary review. If we agree that for most
solid tumors, treatment is stage speciﬁc, then the
clinician needs to know 3 basic pieces of informa-
tion to develop a treatment recommendation:
histologic diagnosis, stage of disease, and perfor-
mance status of the patient. The multidisciplinary
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2078TABLE 1. The clinical/radiographic staging system used at MDACC for adenocarcinoma of the pancreatic head and uncinate
process
Clinical stage of disease
AJCC
stage
Tumor–vessel relationship on computed tomography
SMA Celiac axis CHA** SMV-PV











Patent (may include tumor
abutment or encasement)
Borderline resectable
(only 1 of the 4 required)






1 of the 4 required)






Abbreviations: CHA, common hepatic artery; SMV-PV, superior mesenteric vein-portal vein conﬂuence.
Deﬁnitions: abutment, £180  or £50% of the vessel circumference; encasement, >180  or >50% of the vessel circumference.
* Assumes the technical ability to resect and reconstruct the SMV, PV, or SMV-PV conﬂuence when necessary. Others may consider tumor-
vein abutment/encasement which results in deformity of the vein as borderline resectable.
** Assumes normal vascular anatomy; for example, encasement of the CHA is not a limitation in performing PD when there is an
uninvolved replaced right HA arising from the SMA.
Reprinted with permission from: Wolﬀ RA, et al. Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and
Recommendations for Future Progress. In press: Ann surg Oncol.
TABLE 2. An example of the CT template in use at MDACC for the interpretation of CT scans in patients with a presumed
pancreatic malignancy
CT Characteristic
Tumor size Measured in cm
Tumor location Cephalad head, caudal head, uncinate, body, and tail
Tumor-vein (SMV, PV, SMV-PV conﬂuence) relationship Abutment (£180 ), encasement (>180 ) or occlusion
Tumor-artery (SMA, celiac axis, CHA,
replaced hepatic artery) relationship
Abutment (£180 ), encasement (>180 ) or occlusion
Extent of local tumor based on above descriptions Resectable, borderline resectable, locally advanced
Hepatic arterial anatomy Note all aberrant vessels
Extent of extra-pancreatic disease and location Presence, absence, or borderline (indeterminate for metastasis);
location in liver, peritoneum, lung
Abbreviations: SMV, superior mesenteric vein; PV, portal vein; SMV-PV, superior mesenteric vein-portal vein conﬂuence; SMA, superior
mesenteric artery; CHA, common hepatic artery.
TABLE 3. The general treatment schema used to guide stage-speciﬁc therapy at MDACC for patients with adenocarcinoma of
the pancreas
Clinical stage of disease AJCC stage Treatment options
Resectable I/II 1. Protocol-based, stage-speciﬁc neoadjuvant therapy
2. Off-protocol neoadjuvant therapy (usually gemcitabine-based
chemoradiation)
3. Surgery followed by protocol-based adjuvant therapy for
patients who have undergone an R0/R1 resection
Borderline resectable III 1. Protocol-based, stage-speciﬁc multimodality therapy
2. Off-protocol therapy usually consisting of a gemcitabine doublet
followed by chemoradiation and surgery (if no disease progression)
Locally advanced III 1. Protocol-based stage-speciﬁc multimodality therapy
2. Off-protocol chemoradiation if pain is uncontrolled
3. Off-protocol systemic therapy followed by chemoradiation (if no
disease progression following systemic therapy)
Metastatic IV 1. Protocol-based systemic therapy
2. Off-protocol systemic therapy
3. Best supportive care
EDITORIAL 2079
Ann. Surg. Oncol. Vol. 15, No. 8, 2008review/interaction (whether in an outpatient clinic
or a tumor board environment) enhances cross-
talk between specialties and allows for the devel-
opment of consensus regarding stage-speciﬁc (and
to some degree institution-speciﬁc) treatment
algorithms (Table 3). Having physicians of differ-
ent specialties reach consensus on treatment rec-
ommendations requires that they have meaningful
academic interchange – the multidisciplinary clinic
clearly serves that purpose, but other potentially
less time-consuming alternatives (multidisciplinary
outpatient centers which are disease-specific not
specialty-specific, weekly multidisciplinary confer-
ences, office space allocation which considers
disease orientation not just departmental affilia-
tion) may also be available.
3. Enrollment in clinical trials was greatly enhanced
by the development of the multidisciplinary clinic.
Point well taken, and for a disease with such an
aggressive natural history such as pancreatic
cancer, attention to the enrollment of patients in
clinical trials is our obligation (not our option).
However, the success of such efforts is clearly
inﬂuenced by the presence or absence of an
academic agenda, infrastructure support for clin-
ical trials, and patterns of reimbursement. This
may be a much more complicated problem to ﬁx
for many institutions than the other two examples
cited above.
Last, it is important to emphasize the value of
leadership and interpersonal relationships in the
success or failure of multidisciplinary disease-site
program development. For those who have the group
dynamics that exist among Dr. Pawlik and his
colleagues (even at much smaller levels), such efforts
are fun, academically stimulating, and self-perpetu-
ating. When group dynamics are less favorable, it
may be difficult to maintain consistent focus on the
important goals of patient care, clinical trials, and
professional and programmatic development.
Dr. Pawlik and colleagues are to be congratulated
for bringing objective evidence of beneﬁt to a system
of multidisciplinary care that should be made possi-
ble in many hospitals outside Baltimore.
EDITORIAL 2080
Ann. Surg. Oncol. Vol. 15, No. 8, 2008